A randomized, double-blind, placebo-controlled design phase 2 clinical trial to comparatively evaluate the efficacy and safety of CP-COV03 in patients with mild or moderate COVID-19

Hyundai Bioscience0 个研究点目标入组 300 人开始时间: 待定最近更新: 2023年5月30日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 300

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional Study

入排标准

年龄范围: 19(Year) 至 o Limit（—）
性别: All

入选标准

•1) Subjects who voluntarily determine to participate in this study after listening the detailed information and consent in writing (electronically) to comply with the study requirements.
•2) Adults aged 19 and over at the time of screening
•3) Subjects who are confirmed to have COVID-19 through RT-PCR test or rapid antigen kit test by a specialist within 3 days of randomization
•4) Subjects who have developed one or more of the symptoms of COVID-19* within 5 days of randomization, and have at least two symptoms of 2 or higher among the symptom scores** determined on the day of randomization
•* Symptoms of COVID-19: Fever (38.0? or above), cough, sore throat, headache, muscle pain, chills/tremor, runny nose/stuffy nose, fatigue/malaise, dyspnea/shortness of breath, sickness/nausea, vomiting, diarrhea
•** Symptoms are assessed based on a total of 4 levels: 0=(absent), 1=(mild), 2=(moderate), 3=(severe).
•5) Subjects who are diagnosed as mild or moderate according to the NIH triage criteria at screening and randomization.

排除标准

•1) Subjects who have one or more of the following severe findings at screening:
•- Oxygen saturation (SpO2) less than 94% in indoor air conditions
•- Respiratory rate greater than 30 breaths per minute
•- PaO2/FiO2 < 300 mmHg (Test can be omitted if it is medically unnecessary, when considering oxygen saturation, respiratory rate, etc.)
•- Lung infiltrates >50% on chest imaging
•2) Subjects who require oxygen therapy (e.g., supplemental oxygen, Non-invasive ventilation, invasive ventilation, extracorporeal membrane oxygenation, etc.) or have serious conditions such as respiratory failure, shock, or multiple organ failure, etc.
•3) Subjects who have hypersensitivity to the main active ingredient (niclosamide) and components of the clinical investigational drug
•4) Subjects who have genetic problems such as lactose intolerance, galactose intolerance, Lapp lactase deficiency, and glucose-galactose malabsorption
•5) Subjects with renal impairment (eGFR < 30 mL/min/1.73 m2)
•6) Subjects with hepatic impairment (ALT or AST > 5 times the upper limit of normal organ)
•7) Cirrhosis patients with a Child-Pugh score of B or C
•Ascites None Easily controlled Poorly controlled
•Bilirubin < 2 mg/dL 2~3 mg/dL > 3 mg/dL
•Albumin > 3.5 g/dL 3.0~3.5 g/dL < 3.0 g/dL
•Encephalopathy None Mild Advanced
•Nutritional status Excellent Good Poor
•8) Subjects who have gastrointestinal disorders or undergone surgeries that may affect drug absorption, distribution, metabolism, and excretion (except for simple appendicectomy or hernia surgery)
•9) Those who have received drugs such as antiviral agents, neutralizing antibody therapy, plasma fraction therapy, and immune modulators (cytokine therapy, etc.) for the treatment of COVID-19 infection within 28 days of the screening test. However, after a sufficient drug-free interval, the patient may be eligible for participating in the study
•10) Subjects who have or had one or more of the following infectious diseases:
•- Viral diseases other than COVID-19 that require administration of other antiviral drugs (HIV, HBV, HCV, etc.)
•- Serious infections that require ystemic anti-infective treatment other than COVID-19 infection within 30 days before administration of the investigational drug
•11) Pregnant or lactating women
•12) Fertile women and men who plan to become pregnant or do not intend to use the following appropriate contraceptive methods* during the clinical study and for 3 months after the study termination.
•*hormonal contraception, intrauterine device, double blocking method (both male (condom) and female (contraceptive diaphragm, vaginal sponge or cervical cap) use), sterilization (vasectomy, tubal ligation, etc.)
•13) Subjects who have participated in other clinical trials of a drug/medical device within 28 days of the consent form sign date and have administered/treated with that clinical investigational drugs/medical devices
•14) Subjects who have chronic underlying diseases that are unsuitable for participation in the study in the opinion of the investigator, and who are determined by the investigator to be inappropriate to participate in this clinical study for other reasons

研究者

发起方

Hyundai Bioscience

相似试验

进行中（未招募）

1 期

Dose-ranging study to assess the efficacy, safety, and tolerability of SAR440340 (anti-IL-33 mAb) in patients with moderate-to-severe asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthma

EUCTR2019-003751-10-ITSANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT1,120

已完成

1 期

A randomized, double-blind, placebo-controlled dose-escalation study of AND017 capsules in healthy subjects following oral single and multiple dose administratioAnaemiaBlood - Anaemia

ACTRN12620000725965BalanceBio Pty Ltd78

进行中（未招募）

1 期

EUCTR2019-003751-10-ESSanofi-Aventis Recherche & Developpement1,120

已完成

1 期

Safety, tolerability, pharmacokinetics and pharmacodynamics of KNS366Healthy volunteers. The intended indication for the product under development is damage to secondary organs during a systemic inflammatory response.

ISRCTN10496020Kynos Therapeutics Ltd40

进行中（未招募）

不适用

A randomized, double-blind, placebo-controlled dose selection study with two RP 01 formulations evaluating anti-IgE immunotherapy in allergic patientsMedDRA version: 9.1Level: LLTClassification code 10001738Term: AllergyAllergy

EUCTR2007-006551-39-SEResistentia Pharmaceuticals AB